J. Grudzinski

发表

Beyond the margins: real-time detection of cancer using targeted fluorophores

Eben L. Rosenthal, Kevin W. Eliceiri, Jason M. Warram, 2017, Nature Reviews Clinical Oncology.

Preclinical Characterization of 86/90Y-NM600 in a Variety of Murine and Human Cancer Tumor Models

B. Bednarz, J. Engle, R. Hernandez, 2019, The Journal of Nuclear Medicine.

Impact of PET and MRI threshold-based tumor volume segmentation on patient-specific targeted radionuclide therapy dosimetry using CLR1404

B. Bednarz, J. Kuo, J. Weichert, 2017, Physics in medicine and biology.

Pretreatment CLR 124 Positron Emission Tomography Accurately Predicts CLR 131 Three-Dimensional Dosimetry in a Triple-Negative Breast Cancer Patient.

B. Bednarz, J. Weichert, L. Hall, 2019, Cancer biotherapy & radiopharmaceuticals.

Murine-specific Internal Dosimetry for Preclinical Investigations of Imaging and Therapeutic Agents

B. Bednarz, D. Baiu, M. Otto, 2018, Health physics.

Toward Individualized Voxel-Level Dosimetry for Radiopharmaceutical Therapy.

E. Frey, B. Bednarz, S. Benedict, 2021, International journal of radiation oncology, biology, physics.

Preclinical Pharmacokinetics and Dosimetry Studies of 124I/131I-CLR1404 for Treatment of Pediatric Solid Tumors in Murine Xenograft Models

B. Bednarz, R. Hernandez, D. Baiu, 2019, The Journal of Nuclear Medicine.

pediatric solid tumors in murine xenograft models

B. Bednarz, R. Hernandez, D. Baiu, 2019 .

CLR 125 Auger Electrons for the Targeted Radiotherapy of Triple-Negative Breast Cancer.

Ashley M. Weichmann, B. Bednarz, A. Moser, 2018, Cancer biotherapy & radiopharmaceuticals.

Low-Dose Radiation Potentiates the Propagation of Anti-Tumor Immunity against Melanoma Tumor in the Brain after In Situ Vaccination at a Tumor outside the Brain

B. Bednarz, KyungMann Kim, J. Engle, 2021, Radiation Research.

Application of a whole-body pharmacokinetic model for targeted radionuclide therapy to NM404 and FLT

R. Jeraj, W. Tomé, Alice Nomura, 2012, Physics in medicine and biology.

Clinical Imaging and Dosimetry of a Pan-Cancer Targeting Alkylphosphocholine Analog, [124I]I-NM404

Steve Y. Cho, B. Bednarz, J. Kuo, 2022, Radiation.

Profound immunomodulatory effects of 225Ac-NM600 drive enhanced anti-tumor response in prostate cancer

Zachary T. Rosenkrans, D. McNeel, B. Bednarz, 2022, bioRxiv.

Temporal analysis of type 1 interferon activation in tumor cells following external beam radiotherapy or targeted radionuclide therapy

B. Bednarz, KyungMann Kim, J. Engle, 2021, Theranostics.

TITLE: 177Lu-NM600 targeted radionuclide therapy extends survival in syngeneic murine models of triple-negative breast cancer. RUNNING TITLE: TRT of triple-negative breast cancer

J. Engle, R. Hernandez, J. Weichert, 2019 .

Overview of the First NRG Oncology–National Cancer Institute Workshop on Dosimetry of Systemic Radiopharmaceutical Therapy

J. Humm, R. Wahl, S. Mirzadeh, 2020, The Journal of Nuclear Medicine.

Current Status of Radiopharmaceutical Therapy.

E. Frey, B. Bednarz, S. Benedict, 2020, International journal of radiation oncology, biology, physics.

Development and Validation of RAPID: A Patient-Specific Monte Carlo Three-Dimensional Internal Dosimetry Platform.

Bryan P Bednarz, Abigail E Besemer, You Ming Yang, 2018, Cancer biotherapy & radiopharmaceuticals.

Alkylphosphocholine Analogs for Broad-Spectrum Cancer Imaging and Therapy

P. Pickhardt, J. Kuo, Kyle Swanson, 2014, Science Translational Medicine.

Safety and feasibility of an in situ vaccination and immunomodulatory targeted radionuclide combination immuno-radiotherapy approach in a comparative (companion dog) setting

B. Bednarz, M. Albertini, J. Engle, 2021, PloS one.

Developments in Combining Targeted Radionuclide Therapies and Immunotherapies for Cancer Treatment

R. Hernandez, J. Weichert, J. Grudzinski, 2022, Pharmaceutics.

Low-dose targeted radionuclide therapy renders immunologically cold tumors responsive to immune checkpoint blockade

Amy K. Erbe, B. Bednarz, KyungMann Kim, 2021, Science Translational Medicine.

Radiation to all macroscopic sites of tumor permits greater systemic antitumor response to in situ vaccination

Amy K. Erbe, B. Bednarz, R. Hernandez, 2023, Journal for ImmunoTherapy of Cancer.

PRODUCTION OF MEDICAL ISOTOPES WITH ELECTRON LINACS*

D. Ehst, T. Heltemes, A. Youker, 2017 .

Antitumor efficacy of 90Y-NM600 targeted radionuclide therapy and PD-1 blockade is limited by regulatory T cells in murine prostate tumors

D. McNeel, B. Bednarz, J. Engle, 2022, Journal for ImmunoTherapy of Cancer.

A radiobiological model of metastatic burden reduction for molecular radiotherapy: application to patients with bone metastases

Jian Z. Wang, R. Stewart, W. Tomé, 2017 .

Dosimetric effectiveness of targeted radionuclide therapy based on a pharmacokinetic landscape.

R. Jeraj, J. Weichert, J. Grudzinski, 2010, Cancer biotherapy & radiopharmaceuticals.

Validation of Monte Carlo 131I radiopharmaceutical dosimetry workflow using a 3D‐printed anthropomorphic head and neck phantom

P. Harari, B. Bednarz, B. Cox, 2022, Medical physics.

The biological effectiveness of targeted radionuclide therapy based on a whole-body pharmacokinetic model

R. Jeraj, W. Tomé, J. Weichert, 2010, Physics in medicine and biology.

177Lu-NM600 Targeted Radionuclide Therapy Extends Survival in Syngeneic Murine Models of Triple-Negative Breast Cancer

J. Engle, R. Hernandez, J. Weichert, 2019, The Journal of Nuclear Medicine.

Patient specific treatment planning for systemically administered radiopharmaceuticals using PET/CT and Monte Carlo simulation.

P. Deluca, J. Weichert, H Yoriyaz, 2010, Applied radiation and isotopes : including data, instrumentation and methods for use in agriculture, industry and medicine.

90Y-NM600 targeted radionuclide therapy induces immunologic memory in syngeneic models of T-cell Non-Hodgkin’s Lymphoma

J. Engle, R. Hernandez, J. Weichert, 2019, Communications Biology.

Image-Based Dosimetry in Dogs and Cross-Reactivity with Human Tissues of IGF2R-Targeting Human Antibody

B. Bednarz, E. Dadachova, M. Uppalapati, 2023, Pharmaceuticals.

Targeting of Head and Neck Cancer by Radioiodinated CLR1404 in Murine Xenograft Tumor Models with Partial Volume Corrected Theranostic Dosimetry.

P. Harari, B. Bednarz, R. Hernandez, 2023, Cancer biotherapy & radiopharmaceuticals.

Theranostic Combination of Molecularly Targeted Radiotherapy and Immunotherapy Optimizes Therapeutic Response in a Syngeneic Murine Model of Melanoma

B. Bednarz, S. Gillies, R. Hernandez, 2018 .